Short Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Increases By 15.4%

Enlivex Therapeutics Ltd. (NASDAQ:ENLVGet Free Report) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 261,500 shares, a growth of 15.4% from the February 29th total of 226,600 shares. Based on an average daily volume of 108,300 shares, the short-interest ratio is currently 2.4 days.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ENLV. Jane Street Group LLC lifted its stake in shares of Enlivex Therapeutics by 89.6% in the 1st quarter. Jane Street Group LLC now owns 52,507 shares of the company’s stock valued at $294,000 after purchasing an additional 24,807 shares during the period. UBS Group AG increased its holdings in Enlivex Therapeutics by 73.4% in the third quarter. UBS Group AG now owns 31,871 shares of the company’s stock valued at $136,000 after purchasing an additional 13,490 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in Enlivex Therapeutics in the first quarter valued at about $68,000. Finally, Bank of America Corp DE boosted its holdings in Enlivex Therapeutics by 87.0% during the first quarter. Bank of America Corp DE now owns 6,163 shares of the company’s stock worth $34,000 after buying an additional 2,867 shares during the last quarter. Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Price Performance

Shares of ENLV stock traded up $0.04 on Tuesday, reaching $4.04. 142,863 shares of the stock were exchanged, compared to its average volume of 95,552. The stock has a 50 day moving average price of $3.35 and a 200 day moving average price of $2.45. The stock has a market cap of $75.02 million, a PE ratio of -2.75 and a beta of 1.02. Enlivex Therapeutics has a one year low of $1.20 and a one year high of $4.37.

Enlivex Therapeutics Company Profile

(Get Free Report)

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.

Featured Articles

Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.